Skip to main content
OpenTrials

Clinical trial condition

Paramyxoviridae Infections

Explore clinical trials studying Paramyxoviridae Infections. Study availability and eligibility vary by location and protocol.

20 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Paramyxoviridae Infections trial results

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922

Conditions
COVID-19, Coronaviridae Infections, Coronavirus Infections, +14 more
Locations
  • City of Hope cancer Center Duarte, California, United States
  • University of California Davis Health System Sacramento, California, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • University of Iowa Health Care Iowa City, Iowa, United States
View all 28 locations
View Trial Details
Recruiting

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

NCT06999603

Conditions
Adenoviridae Infections, Coronaviridae Infections, Coronavirus Infections, +15 more
Locations
  • University of California - Davis Sacramento, California, United States
  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center Torrance, California, United States
  • NCH Pulmonary Critical Care Naples, Florida, United States
  • Emory University Atlanta, Georgia, United States
View all 67 locations
View Trial Details
Completed

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

NCT06604767

Conditions
Infections, Metapneumovirus Infection, Mononegavirales Infections, +7 more
Locations
  • Investigational Site Number : 0360006 Blacktown, New South Wales, Australia
  • Investigational Site Number : 0360001 Botany, New South Wales, Australia
  • Investigational Site Number : 0360009 Brookvale, New South Wales, Australia
  • Investigational Site Number : 0360005 Kanwal, New South Wales, Australia
View Trial Details
Completed

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

NCT06850051

Conditions
Healthy Volunteers, Human Metapneumovirus Vaccination, Infections, +11 more
Locations
  • Paratus Clinical Blacktown, New South Wales, Australia
  • Paratus Clinical Herston, Queensland, Australia
  • University of Sunshine Coast Clinical Trials Morayfield, Queensland, Australia
  • University of Sunshine Coast Clinical Trials South Brisbane, Queensland, Australia
View Trial Details
Completed

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348

Conditions
Human Metapneumovirus and Human Parainfluenza Infection, Infections, Mononegavirales Infections, +3 more
Locations
  • Central Research Associates Inc Birmingham, Alabama, United States
  • Meridian Clinical Research Washington D.C., District of Columbia, United States
  • Clinical Research Prime Idaho Falls, Idaho, United States
  • Heartland Research Associates LLC El Dorado, Kansas, United States
View all 19 locations
View Trial Details
Completed

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625

Conditions
Coronaviridae Infections, Coronavirus, Coronavirus Infections, +13 more
Locations
  • Children's Hospital Colorado Infectious Disease Aurora, Colorado, United States
  • Denver Health Medical Center Denver, Colorado, United States
  • Denver Veteran's Administration Medical Center Denver, Colorado, United States
  • Veterans Affairs Medical Center, Washington, DC Washington D.C., District of Columbia, United States
View Trial Details

Related conditions